What are the Toxicological Concerns with MDR TB Treatment?
Second-line drugs used in MDR TB treatment are associated with significant adverse drug reactions (ADRs) and toxicities. Common toxicological concerns include nephrotoxicity, ototoxicity, hepatotoxicity, and peripheral neuropathy. For instance, aminoglycosides like amikacin can cause irreversible hearing loss (ototoxicity) and kidney damage (nephrotoxicity). Monitoring and managing these toxicities is critical to ensure patient compliance and successful treatment outcomes.
